JP4566290B2 - 癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体 - Google Patents

癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体 Download PDF

Info

Publication number
JP4566290B2
JP4566290B2 JP54643798A JP54643798A JP4566290B2 JP 4566290 B2 JP4566290 B2 JP 4566290B2 JP 54643798 A JP54643798 A JP 54643798A JP 54643798 A JP54643798 A JP 54643798A JP 4566290 B2 JP4566290 B2 JP 4566290B2
Authority
JP
Japan
Prior art keywords
seq
chain
ricin
toxin
protease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
JP54643798A
Other languages
English (en)
Japanese (ja)
Other versions
JP2001523961A (ja
JP2001523961A5 (cg-RX-API-DMAC7.html
Inventor
ボーグフォード,ソール
Original Assignee
ツインストランド・ホールディングス・インコーポレイテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ツインストランド・ホールディングス・インコーポレイテッド filed Critical ツインストランド・ホールディングス・インコーポレイテッド
Publication of JP2001523961A publication Critical patent/JP2001523961A/ja
Publication of JP2001523961A5 publication Critical patent/JP2001523961A5/ja
Application granted granted Critical
Publication of JP4566290B2 publication Critical patent/JP4566290B2/ja
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/415—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from plants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2799/00—Uses of viruses
    • C12N2799/02—Uses of viruses as vector
    • C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Biophysics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Botany (AREA)
  • Virology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
JP54643798A 1997-04-30 1998-04-30 癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体 Expired - Lifetime JP4566290B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US4514897P 1997-04-30 1997-04-30
US60/045,148 1997-04-30
US6371597P 1997-10-29 1997-10-29
US60/063,715 1997-10-29
PCT/CA1998/000394 WO1998049311A2 (en) 1997-04-30 1998-04-30 Ricin-like toxin variants for treatment of cancer, viral or parasitic infections

Publications (3)

Publication Number Publication Date
JP2001523961A JP2001523961A (ja) 2001-11-27
JP2001523961A5 JP2001523961A5 (cg-RX-API-DMAC7.html) 2007-01-11
JP4566290B2 true JP4566290B2 (ja) 2010-10-20

Family

ID=26722431

Family Applications (1)

Application Number Title Priority Date Filing Date
JP54643798A Expired - Lifetime JP4566290B2 (ja) 1997-04-30 1998-04-30 癌、ウイルスまたは寄生虫感染を治療するためのリシン様毒素変異体

Country Status (8)

Country Link
US (3) US6593132B1 (cg-RX-API-DMAC7.html)
EP (1) EP0977862B8 (cg-RX-API-DMAC7.html)
JP (1) JP4566290B2 (cg-RX-API-DMAC7.html)
AT (1) ATE437229T1 (cg-RX-API-DMAC7.html)
AU (1) AU7023798A (cg-RX-API-DMAC7.html)
CA (1) CA2288943C (cg-RX-API-DMAC7.html)
DE (1) DE69840998D1 (cg-RX-API-DMAC7.html)
WO (1) WO1998049311A2 (cg-RX-API-DMAC7.html)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6361946B1 (en) 1997-02-05 2002-03-26 Licentia Ltd Vascular endothelial growth factor C (VEGF-C) protein and gene, mutants thereof, and uses thereof
US7247715B2 (en) * 1997-04-30 2007-07-24 Twinstrand Therapeutics Inc. Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
AU7636800A (en) 1999-10-04 2001-05-10 Twinstrand Therapeutics Inc. Improved ricin-like toxins for treatment of cancer
GB0100551D0 (en) * 2001-01-09 2001-02-21 Queen Mary & Westfield College Protein
EP1483298A4 (en) 2002-02-11 2007-03-14 Zymogenetics Inc MATERIALS AND METHODS FOR PREPARING DIMERED GROWTH FACTORS
AU2004257206A1 (en) * 2003-07-10 2005-01-27 Wyeth Holdings Corporation Recombinant expression of Streptococcus pyogenes cysteine protease and immunogenic compositions thereof
EP1730282A4 (en) * 2004-03-24 2007-05-09 Twinstrand Therapeutics Inc GLYCOSYLATION VARIANTS OF RICINE-LIKE PROTEINS
ATE467641T1 (de) * 2004-03-26 2010-05-15 Molecular Templates Inc Bibliothek von toxin mutanten und deren verwendung
US20060024722A1 (en) * 2004-07-30 2006-02-02 Mark Fischer-Colbrie Samples for detection of oncofetal fibronectin and uses thereof
DE102005002978B4 (de) * 2005-01-21 2013-04-25 Merz Pharma Gmbh & Co. Kgaa Rekombinante Expression von Proteinen in einer disulfidverbrückten, zweikettigen Form
CA2664549A1 (en) 2005-09-26 2007-03-29 University Health Network Library from toxin mutants, and methods of using same
DE602006012358D1 (de) * 2005-11-18 2010-04-01 Dabur Pharma Ltd Zielgerichtete fusionsproteine für die krebstherapie
WO2008157263A2 (en) * 2007-06-15 2008-12-24 Arkansas State University Methods of delivery of molecules to cells using a ricin subunit and compositions relating to same
EP2379720B1 (en) 2009-01-20 2016-08-17 Alona Zilberberg Mir-21 promoter driven targeted cancer therapy
US9321847B2 (en) * 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
US10513539B2 (en) 2011-02-10 2019-12-24 Ruprecht-Karls-Universitat Heidelberg Hydrophobic modified peptides and their use for liver specific targeting
CN103402546B (zh) 2011-02-10 2018-04-13 海德堡鲁普雷希特卡尔斯大学 用于肝特异性诊断的疏水性修饰肽
WO2012123755A1 (en) 2011-03-17 2012-09-20 The University Of Birmingham Re-directed immunotherapy
JP7134461B2 (ja) * 2018-03-23 2022-09-12 国立大学法人金沢大学 マラリア治療剤、マラリア予防剤及び抗マラリア自然免疫賦活剤
KR102698801B1 (ko) 2020-12-30 2024-08-29 호크아이 바이오 리미티드 바이오마커 검출을 위한 순수 그래핀 기반 바이오센서 및 관련 코어 입자, 재료 구성 방법 및 시스템
TW202328170A (zh) * 2021-09-14 2023-07-16 美商艾希利歐發展股份有限公司 可裂解連接子
WO2025151752A1 (en) 2024-01-10 2025-07-17 Xilio Development, Inc. Masked il-2 cytokines and methods of use thereof

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2442A (en) 1842-02-01 Floating dry-dock
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
EP0145111B1 (en) * 1983-07-15 1990-05-09 The University Of Warwick Dna sequence coding for a plant toxin of the ricin type, or a portion thereof
US4736866B1 (en) 1984-06-22 1988-04-12 Transgenic non-human mammals
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (en) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Chimeric receptors by dna splicing and expression
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
GB8607679D0 (en) 1986-03-27 1986-04-30 Winter G P Recombinant dna product
US4869903A (en) 1987-05-29 1989-09-26 Genelabs Incorporated Method of selectively inhibiting HIV
WO1990010457A1 (en) 1989-03-14 1990-09-20 New York University Method of treating hiv infections using immunotoxins
US5128460A (en) 1989-04-04 1992-07-07 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5101025A (en) 1989-04-04 1992-03-31 Genelabs Incorporated Recombinant trichosanthin and coding sequence
US5248606A (en) * 1990-06-11 1993-09-28 Dowelanco Dna encoding inactive precursor and active forms of maize ribosome inactivating protein
GB9021679D0 (en) 1990-10-05 1990-11-21 Gorman Scott David Antibody preparation
US5677274A (en) * 1993-02-12 1997-10-14 The Government Of The United States As Represented By The Secretary Of The Department Of Health And Human Services Anthrax toxin fusion proteins and related methods
EP0909322B1 (en) * 1996-04-30 2005-11-16 Twinstrand Therapeutics Inc. Antiviral ricin-like proteins

Also Published As

Publication number Publication date
DE69840998D1 (de) 2009-09-03
ATE437229T1 (de) 2009-08-15
EP0977862A2 (en) 2000-02-09
JP2001523961A (ja) 2001-11-27
US7375186B2 (en) 2008-05-20
US20110144004A1 (en) 2011-06-16
AU7023798A (en) 1998-11-24
CA2288943C (en) 2011-02-01
EP0977862B1 (en) 2009-07-22
CA2288943A1 (en) 1998-11-05
WO1998049311A3 (en) 1999-02-11
WO1998049311A2 (en) 1998-11-05
US6593132B1 (en) 2003-07-15
EP0977862B8 (en) 2009-09-16
US20040009551A1 (en) 2004-01-15

Similar Documents

Publication Publication Date Title
US20110144004A1 (en) Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
US8524241B2 (en) Fusion proteins comprising a fragment of Vibrio cholerae exotoxin A
US20110178026A1 (en) Ricin-like toxins for treatment of cancer
KR101413480B1 (ko) Sparc 결합 펩티드와 이들의 용도
AU716564B2 (en) Protease-activatable pseudomonas exotoxin A-like proproteins
JP2685742B2 (ja) 組織型及びウロキナーゼ型プラスミノーゲン活性化因子インヒビター及びそれを使用する固相分析方法
WO2012038950A1 (en) Activatable toxin complexes comprising a cleavable inhibitory peptide
CA2668017A1 (en) Improved conjugates
KR100204258B1 (ko) 재조합 고양이 코로나바이러스 에스 단백질
EP0909322B1 (en) Antiviral ricin-like proteins
US6803358B1 (en) Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
ES2431548T3 (es) Proteínas inhibidoras de una proteasa y su uso
US7247715B2 (en) Ricin-like toxin variants for treatment of cancer, viral or parasitic infections
CA2161772A1 (en) Fibrin-targeted inhibitors of thrombin
US20180215831A1 (en) Antibody Derivatives with Conditionally Enabled Effector Function
JP2012512183A (ja) 改変された孔形成性タンパク質プロアエロリシンを用いた前立腺炎の処置のための方法
JP2007530019A (ja) リシン様タンパク質のグリコシル化変種
CN113728012A (zh) 用于治疗可扩张组织的组合物和方法

Legal Events

Date Code Title Description
A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20050427

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20060704

A524 Written submission of copy of amendment under article 19 pct

Free format text: JAPANESE INTERMEDIATE CODE: A524

Effective date: 20060704

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20080108

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20080407

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20090203

RD02 Notification of acceptance of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7422

Effective date: 20090417

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20090417

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20090424

A602 Written permission of extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A602

Effective date: 20090608

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20090803

A711 Notification of change in applicant

Free format text: JAPANESE INTERMEDIATE CODE: A711

Effective date: 20090803

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20100706

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20100804

R150 Certificate of patent or registration of utility model

Free format text: JAPANESE INTERMEDIATE CODE: R150

FPAY Renewal fee payment (event date is renewal date of database)

Free format text: PAYMENT UNTIL: 20130813

Year of fee payment: 3

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

EXPY Cancellation because of completion of term